Marco Ruella, MD

faculty photo
Assistant Professor of Medicine
Department: Medicine
Graduate Group Affiliations

Contact information
South Tower 8-112
Perelman Center for Advanced Medicine
3400 Civic Center Blvd
Philadelphia, PA 191004
Office: 215-746-4880
Fax: 215-573-3638
Lab: 215-573-8538
MD (Medical Degree)
University of Torino, Italy , 2007.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Dr. Ruella treat patients affected by hematological cancers and specializes in immunotherapy approaches.

Description of Research Expertise

Dr. Ruella's laboratory focuses on the mechanisms of relapse after chimeric antigen receptor T cell (CART) immunotherapies with the goal of rationally design innovative combined immunotherapies for relapsing/refractory leukemia and lymphoma.

Marco Ruella, MD, is Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania. His research focuses on the study of the mechanisms of relapse after chimeric antigen receptor T cell (CART) immunotherapies with the goal of rationally designing combined innovative immunotherapies for relapsing/refractory leukemia and lymphoma. He is the author of numerous peer-reviewed publications on targeted immunotherapies for hematological cancers and is an inventor in several patents on CAR T therapy. His work has been recognized through numerous awards including the inaugural SITC EMD-Serono Cancer Immunotherapy Clinical Fellowship (2014), the AACR-BMS Oncology Fellowship in Clinical Cancer Research (2015), the ASH Scholar Award (2016), a NIH K99-R00 award (2017), the “Paola Campese” Award Leukemia Research (2017), the Cancer Support Community Award (2018), and most recently the 2018 American Society of Hematology Joanne Levy, MD, Memorial Award for Outstanding Achievement. Dr. Ruella obtained his medical degree with high honors and completed his specialization in clinical hematology at the University of Torino, Italy. After completing his fellowship, he was an attending physician in the Hematology and Cell Therapy Division of the Mauriziano Hospital and an Instructor at the Biotechnology School at the University of Torino. From 2012, he was a postdoctoral fellow, and then an instructor at the University of Pennsylvania in the Center for Cellular Immunotherapies where he worked with Drs. June and Gill until appointment to his current position in 2018.

Selected Publications

Wagner DL, Fritsche E, Pulsipher M, Ahmed N, Hamieh M, Hegde M, Ruella M, Savoldo, B, Shah N, Turtle C, Wayne A, and Abou-El-Enein M. : Immunogenicity of CAR-T cells in cancer therapy. Nature Reviews Clinical Oncology Epub, February 2021.

Guruprasad P, Lee Y.G., Kim K.H. and Ruella M. : The Current Landscape of Single-Cell Transcriptomics for Cancer Immunotherapy. Journal of Experimental Medicine January 2021 Notes: (available on 2021-07-04).

Ghilardi G., Braendstrup P., Chong E.A., Schuster S.J., Svoboda J. and Ruella M.: CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before. British Journal of Haematology Epub, November 2020.

Svoboda J, Bair SM, Landsburg DJ, Nasta SD, Nagle SJ, Barta SK, Khan N, Filicko-O'Hara J, Gaballa S, Strelec L, Chong E, Mitnick S, Waite TS, King C, Ballard H, Youngman M, Gerson J, Plastaras JP, Maity A, Bogusz AM, Hung SS, Nakamura H, Nejati R, Steidl C, Lim M, Ruella M, Schuster : Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. SJ.Haematologica. 2020 May 15:haematol.2019.238675. doi: 10.3324/haematol.2019.238675. Online ahead of print. May 2020.

Cerrano M, Ruella M, Perales MA, Vitale C, Faraci DG, Giaccone L, Coscia M, Maloy M, Sanchez-Escamilla M, Elsabah H, Fadul A, Maffini E, Pittari G, Bruno B. : The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. Front Immunol. 2020 May 12;11:888. doi: 10.3389/fimmu.2020.00888. eCollection 2020. May 2020.

Nathan Singh, Yong Lee, Pranali Ravikumar, Olga Shestova, Katharina Hayer, Seok Hong, Xueqing Lu, Raymone Pajarillo, Sangya Agarwal, Shunichiro Kuramitsu, Elena Orlando, Karen Mueller, Charly Good, Shelley L. Berger, Ophir Shalem, Matthew Weitzman, Noelle Frey, Shannon Maude, Stephan Grupp, Carl June, Saar Gill, and Marco Ruella. : Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T cell dysfunction. Cancer Discovery April 2020.

Braendstrup P, Levine B.L., Ruella M. : The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy Page: 57-69, Feb 2020.

Chun I, Kim H.K., Chiang YH, Xie W, Lee Y.G., Pajarillo R, Rotolo A, Shestova O, Hong S.J., Abdel-Mohsen M, Wysocka M, Ballard H.J., Barrett D.M., Posey A.D., Powell Jr. D, Gill S.I., Schuster, S.J., Barta, S.K., Rook A.H., June C.H., and Ruella M : CRISPR-Cas9 Knock out of CD5 Enhances the Anti-Tumor Activity of Chimeric Antigen Receptor T Cells American Society of Hematology Annual Meeting Virtual (554), 2020.

Ghilardi G., Braendstrup P., Chong E.A., Schuster S.J., Svoboda J. and Ruella M. : CAR-T TREK through the Lymphoma Universe: to Boldly Go Where No Other Therapy Has Gone Before. British Journal of Haematology. accepted, 2020.

Mondello P, Strati P, Merryman R.W., Joffe E., Ruella M, Seshan V., St. Pierre F, Major A, Pophali P, Fiasconaro M, Ho C.I., Neal E, Lai CM, Spilberg G, Rajguru S, Svoboda J, Witzig T.E. Smith S.M., Armand P, Nastoupil L.J., Ansell S.M., Zelenetz A.D. Younes A, and Salles G : R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. American Society of Hematology Annual Meeting Virtual (2041), 2020.

back to top
Last updated: 09/16/2021
The Trustees of the University of Pennsylvania